Skip to main content
Premium Trial:

Request an Annual Quote

SBS Names New President; Charles River Hires Invitrogen Alumnus; NimbleGen and Biotage Flesh Out Boards

NEW YORK (GenomeWeb News) — Ricardo Macarron has been named president of the Society for Biomolecular Sciences.
Macarron, vice president of compound management at GlaxoSmithKline, was an SBS board member and is an editor of the SBS’ Journal of Biomolecular Screening.

Charles River Laboratories International has appointed Cheri Walker to the post of corporate senior vice president of corporate development.
Before coming to Charles River, Walker was vice president of mergers and acquisitions for Qiagen Sciences and worked in corporate development and in operations at Invitrogen.

Gregg Fergus has joined NimbleGen’s board of directors, the company said this week.
Fergus formerly was senior vice president of sales and global operations at Affymetrix and was CCO at Cellular Dynamics and Stem Cell Products.
Fergus also has consulted for Caden Biosciences and was an executive in residence at Baird Venture Partners.

Biotage has named Ove Mattsson chairman of the board, and has re-elected as directors Thomas Eklund, Annika Espander, Staffan Lindstrand, Anders Rydin, Bengt Samuelsson,and Mathias Uhlén.
The company has added Axel Broms and Per-Olof Eriksson as new board members.
The appointments took place at Biotage’s annual meeting this week, at which the company voted to set aside SEK1.4 million ($209,000) in remuneration for its board. Of this amount, the chairman will receive SEK 400,000 while other directors not employed by the company will receive SEK125,000.
Biotage also said the members of the auditing committee will receive an aggregate fee of not more than SEK100,000, of which the chairman will receive SEK50,000 and other members will receive SEK25,000 each.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.